白蛋白结合型紫杉醇联合雷莫西尤单抗二线治疗晚期胃癌的II期研究
疾病控制率92.9%,中位无进展生存期7.6个月,毒性可管理,未见治疗相关死亡,生活质量未恶化。
要点
- 白蛋白结合型紫杉醇联合雷莫西尤单抗二线治疗晚期胃癌的客观缓解率达54.8%,达到主要终点。
- 中位无进展生存期7.6个月,疾病控制率92.9%,总生存期数据尚未成熟。
- 主要3/4级不良事件为中性粒细胞减少(76.7%),毒性可管理,无治疗相关死亡。
核心结论
- 白蛋白结合型紫杉醇联合雷莫西尤单抗在既往治疗的晚期胃癌中显示出有前景的抗肿瘤活性和可管理的毒性,可能是有用的二线治疗选择。
主要发现
- 独立评审委员会评估的客观缓解率为54.8%(90%CI 41.0-68.0),达到主要终点。
- 疾病控制率为92.9%(95%CI 80.5-98.5)。
- 独立评审委员会评估的中位无进展生存期为7.6个月(95%CI 5.4-8.1),中位总生存期在数据截止时未达到。
- 主要治疗相关3/4级不良事件包括中性粒细胞计数减少(76.7%)、白细胞计数减少(27.9%)、贫血(11.6%)、食欲下降(7.0%)、发热性中性粒细胞减少(4.7%)、高血压(4.7%)和蛋白尿(4.7%)。
- 未发生治疗相关死亡,研究治疗期间未观察到生活质量恶化。
关键数值与推荐
- 给药方案:白蛋白结合型紫杉醇100 mg/m2静脉注射,第1、8、15天;雷莫西尤单抗8 mg/kg静脉注射,第1、15天;28天为一周期。
- 主要终点为独立评审委员会评估的客观缓解率,次要终点包括无进展生存期、总生存期、疾病控制率、安全性和生活质量。
临床怎么用
- 对于一线化疗失败的晚期胃癌患者,可考虑白蛋白结合型紫杉醇联合雷莫西尤单抗作为二线治疗选择。
- 治疗期间需重点监测中性粒细胞减少等血液学毒性,但整体毒性可管理且无治疗相关死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nanoparticle albumin-bound (nab)-paclitaxel was developed to improve paclitaxel solubility and does not need premedication to avoid infusion-related reactions associated with solvent-based (sb)-paclitaxel. We conducted a phase II trial to investigate the efficacy and safety of nab-paclitaxel plus ramucirumab combination therapy for previously treated advanced gastric cancer. PATIENTS AND METHODS: Patients with unresectable advanced gastric cancer refractory to first-line chemotherapy were administered nab-paclitaxel 100 mg/m2 intravenously on days 1, 8 and 15, plus ramucirumab 8 mg/kg intravenously on days 1 and 15 of a 28-day cycle. The primary end-point was Independent Review Committee (IRC)-assessed overall response rate (ORR). Secondary end-points were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), safety and quality of life (QOL). RESULTS: Forty-five patients were enrolled; 43 received the study treatment. The ORR assessed by the IRC was 54.8% (90% confidence interval [CI] 41.0-68.0) and the primary end-point was met. The DCR was 92.9% (95% CI 80.5-98.5). The IRC-assessed median PFS was 7.6 months (95% CI 5.4-8.1). The median OS was not reached at the data cutoff. The main treatment-related grade 3 or 4 adverse events were decreased neutrophil count (76.7%), decreased white blood cell count (27.9%), anaemia (11.6%), decreased appetite (7.0%), febrile neutropenia (4.7%), hypertension (4.7%) and proteinuria (4.7%). No treatment-related deaths occurred. No QOL deterioration was observed during study treatment. CONCLUSION: Nab-paclitaxel plus ramucirumab combination therapy shows promising activity and manageable toxicities and could be a useful second-line treatment option for patients with previously treated advanced gastric cancer.
引用
- Bando H, Shimodaira H, Fujitani K, et al. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer. 2018. PMID: 29353164. doi:10.1016/j.ejca.2017.11.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。